{{Rsnum
|rsid=4916041
|Gene=DNAJC6
|Chromosome=1
|position=65316975
|Orientation=plus
|GMAF=0.3953
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=DNAJC6
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 35.4 | 40.7 | 23.9
| HCB | 12.4 | 43.1 | 44.5
| JPT | 16.8 | 45.1 | 38.1
| YRI | 6.1 | 32.0 | 61.9
| ASW | 12.3 | 36.8 | 50.9
| CHB | 12.4 | 43.1 | 44.5
| CHD | 10.1 | 43.1 | 46.8
| GIH | 19.8 | 45.5 | 34.7
| LWK | 7.3 | 30.0 | 62.7
| MEX | 15.5 | 39.7 | 44.8
| MKK | 8.3 | 46.2 | 45.5
| TSI | 24.5 | 59.8 | 15.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4916041
|Name_s=
|Gene_s=DNAJC6
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00006. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109371
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4916041
|overall_frequency_n=49
|overall_frequency_d=116
|overall_frequency=0.422414
|n_genomes=34
|n_genomes_annotated=0
|n_haplomes=45
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}